Edge Therapeutics Overview

  • Founded
  • 2008
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Edge Therapeutics General Information

Description

Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Drug Discovery
Primary Office
  • 300 Connell Drive
  • Suite 4000
  • Berkeley Heights, NJ 07922
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Edge Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 18-Mar-2019 00000 Completed Generating Revenue/Not Profitable
9. Secondary Transaction - Open Market 31-Mar-2018 00000 Completed Generating Revenue/Not Profitable
8. IPO 01-Oct-2015 000.00 00000 00000 Completed Generating Revenue/Not Profitable
7. Later Stage VC (Series C2) 08-Apr-2015 0000 000.00 Completed Generating Revenue
6. Later Stage VC (Series C1) 13-Nov-2014 000.00 000.00 Completed Generating Revenue
5. Mezzanine 08-Sep-2014 00.000 0000 Completed Generating Revenue
4. Early Stage VC 18-Mar-2013 00.000 00.000 Completed Generating Revenue
3. Early Stage VC 13-Sep-2012 00000 00000 Completed Startup
2. Early Stage VC 23-Jun-2011 $220K $854K Completed Startup
1. Early Stage VC (Series A) 08-Nov-2010 $634K $634K Completed Startup
To view Edge Therapeutics’s complete valuation and funding history, request access »

Edge Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the
Other Healthcare Technology Systems
Berkeley Heights, NJ
00000
000000&0 00000

00000 00

aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cil
0000 000000000
Cambridge, MA
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

00000 00

d minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. D
00000 0000000000 0000000000 0000000
San Francisco, CA
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Edge Therapeutics Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Relay Therapeutics Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
00000 00000000 Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
0 000000000000 Venture Capital-Backed Salt Lake City, UT 00 000.00 0000000000 0 000.00
000000 000000 Formerly VC-backed Laval, Canada 00 000.00 000000000 000.00
0000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
You’re viewing 5 of 17 competitors. Get the full list »

Edge Therapeutics Executive Team (16)

Name Title Board Seat Contact Info
Brian Leuthner Chief Executive Officer, President & Director
Daniel Brennan Chief Operating Officer
Albert Marchio II Chief Accounting & Operations Officer
R. Loch Macdonald Ph.D Chief Scientific Officer & Director
Carl Soranno JD Co-Founder & Corporate Secretary
You’re viewing 5 of 16 executive team members. Get the full list »

Edge Therapeutics Board Members (8)

Name Representing Role Since
Isaac Blech Self Vice Chairman of the Board of Director 000 0000
James Loughlin Edge Therapeutics Board Member 000 0000
Robert Spiegel MD Self Board Member 000 0000
Sol Barer Ph.D Self Chairman of the Board 000 0000
You’re viewing 4 of 8 board members. Get the full list »

Edge Therapeutics Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alpine Meridian Venture Capital Minority 000 0000 000000 0
BioMed Ventures Corporate Venture Capital Minority 000 0000 000000 0
Biobrit Venture Capital Minority 000 0000 000000 0
Delaware Crossing Investor Group Angel Group Minority 000 0000 000000 0
Franklin Templeton Investments Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »